Categories Earnings, Health Care
Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views
Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to $35.54 million in Q2 from $3.36 million in the prior year. Analysts had expected the company to post a loss of 42 cents per share on revenue of $39.58 million for the recently ended quarter.
As the company reported mixed results, shares of Novavax were trading in the red zone immediately after the earnings announcement. However, NVAX stock turned to positive territory later in the after-market hours.
“Since identifying a candidate vaccine to address the COVID-19 pandemic in March, we’ve secured significant funding, implemented global manufacturing capacity and completed and reported our successful Phase 1 trial,” said CEO Stanley Erck.
During the second quarter, Novavax secured $2 billion in funding for development and commercialization of its COVID vaccine NVX-CoV2373 program, which included funding from:
- U.S. Government’s Operation Warp Speed (OWS)
- U.S. Department of Defense (DoD)
- Coalition for Epidemic Preparedness Innovations (CEPI)
NVAX stock, which hit a new 52-week high ($189.40) last week, closed up 4.83% today at $178.51.
Most Popular
Highlights of Aurora Cannabis (ACB) Q4 2020 earnings report
Aurora Cannabis, Inc. (NYSE: ACB) reported a wider loss for the fourth quarter of 2020, hurt by a 5% decrease in revenues. The company’s stock fell sharply during Tuesday’s after-hours
Infographic: Stitch Fix Q4 2020 earnings
Stitch Fix (NASDAQ: SFIX) reported fourth-quarter 2020 financial results after the closing bell on Tuesday. The company reported an 11% increase in Q4 revenues to $443.4 million, beating Wall Street
Nike Inc. (NKE) stock spikes after beating Q1 2021 estimates
Nike Inc.'s (NYSE: NKE) profit and revenue in the first quarter of fiscal 2021 surpassed the market's estimates and sent the NKE stock up by about 7% in the extended